Works matching IS 00071048 AND DT 2017 AND VI 176 AND IP 3


Results: 22
    1
    3
    4
    5
    6

    Prognostic importance of CD56 expression in intermediate risk acute myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 3, p. 498, doi. 10.1111/bjh.13971
    By:
    • Coelho ‐ Silva, Juan L;
    • Carvalho, Luany E;
    • Oliveira, Mayara M;
    • Franca ‐ Neto, Pedro L;
    • Andrade, Adryanna T;
    • Lima, Aleide S;
    • Bezerra, Matheus F;
    • Lima, Marinus M;
    • Neves, Maria A;
    • Fonseca, Julia M;
    • Barros ‐ Correia, Maria C;
    • Machado, Cintia G;
    • Bezerra, Marcos A;
    • Matos, Daniel M;
    • Lucena ‐ Araujo, Antonio R
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13

    Issue Information.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 3, p. 331, doi. 10.1111/bjh.14350
    Publication type:
    Article
    14

    Guidelines for the use of platelet transfusions.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 3, p. 365, doi. 10.1111/bjh.14423
    By:
    • Estcourt, Lise J.;
    • Birchall, Janet;
    • Allard, Shubha;
    • Bassey, Stephen J.;
    • Hersey, Peter;
    • Kerr, Jonathan Paul;
    • Mumford, Andrew D.;
    • Stanworth, Simon J.;
    • Tinegate, Hazel
    Publication type:
    Article
    15
    16
    17

    Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 3, p. 431, doi. 10.1111/bjh.14428
    By:
    • Ringdén, Olle;
    • Labopin, Myriam;
    • Schmid, Christoph;
    • Sadeghi, Behnam;
    • Polge, Emmanuelle;
    • Tischer, Johanna;
    • Ganser, Arnold;
    • Michallet, Mauricette;
    • Kanz, Lothar;
    • Schwerdtfeger, Rainer;
    • Nagler, Arnon;
    • Mohty, Mohamad
    Publication type:
    Article
    18
    19
    20
    22

    Ublituximab ( TG-1101), a novel glycoengineered anti- CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.

    Published in:
    British Journal of Haematology, 2017, v. 176, n. 3, p. 412, doi. 10.1111/bjh.14447
    By:
    • Sharman, Jeff P.;
    • Farber, Charles M.;
    • Mahadevan, Daruka;
    • Schreeder, Marshall T.;
    • Brooks, Heather D.;
    • Kolibaba, Kathryn S.;
    • Fanning, Suzanne;
    • Klein, Leonard;
    • Greenwald, Daniel R.;
    • Sportelli, Peter;
    • Miskin, Hari P.;
    • Weiss, Michael S.;
    • Burke, John M.
    Publication type:
    Article